Table 3.
Hazard ratios of CIN3+ during up to 19 years of follow-up in 65 women with persistent HPV16 infection at baseline, according to expression level of TMEM45A, p16INK4a and SERPINB5 as measured by quantitative real-time PCR at baseline
| Main analysis | Sensitivity analysis using midpoint of time interval | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Expression level | CIN3+ | Age-adjusted HR of CIN3+ | (95% CI) | Age-adjusted HR of CIN3+ | (95% CI) | |||
|
|
||||||||
| N | n | (%) | ||||||
| TMEM45A | < Median | 32 | 11 | (34.4) | 1.0 | (ref) | 1.0 | (ref) |
| ≥ Median | 33 | 20 | (60.6) | 3.1 | (1.4-6.7) | 3.6 | (1.7-7.9) | |
| Continuous (per 10-fold increase) | 65 | 31 | (47.7) | 1.6 | (1.1-2.3) | 1.2 | (1.1-1.3) | |
| p16INK4a* | < Median | 30 | 13 | (43.3) | 1.0 | (ref) | 1.0 | (ref) |
| ≥ Median | 30 | 18 | (60.0) | 1.8 | (0.9-3.7) | 2.2 | (1.0-4.5) | |
| Continuous (per 10-fold increase) | 60 | 31 | (51.7) | 1.6 | (1.1-2.5) | 1.2 | (1.1-1.4) | |
| SERPINB5 | < Median | 33 | 10 | (30.3) | 1.0 | (ref) | 1.0 | (ref) |
| ≥ Median | 32 | 21 | (65.6) | 4.2 | (1.9-9.3) | 4.8 | (2.2-10.7) | |
| Continuous (per 10-fold increase) | 65 | 31 | (47.7) | 1.8 | (1.2-2.7) | 1.2 | (1.1-1.3) | |
*
Five women with missing p16INK4a values were excluded.
CI, Confidence interval; CIN3+, Cervical intraepithelial neoplasia grade 3 or worse; HPV, Human papillomavirus; HR, Hazard ratio; (ref), reference group.